NCT05641610View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2028

Conditions
Hemophilia B
Interventions
GENETIC

ZS801

A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose levels are as follows: 2.0×10\^12vg/kg, 5.0×10\^12vg/kg, 1.0×10\^13vg/kg.

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER